Login to Your Account



EPIX Lands Big $1.2B-Plus Deal For GPCRs With GSK

By Karen Pihl-Carey


Wednesday, December 13, 2006
In a deal that could result in $1.2 billion in milestone payments - on top of a $35 million up-front payment - EPIX Pharmaceuticals Inc. signed with GlaxoSmithKline plc to discover, develop and market drugs that target four G-protein-coupled receptors. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription